Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.

European journal of haematology - 1 Sept 2010

Willander Kerstin, Ungerbäck Jonas, Karlsson Karin, Fredrikson Mats, Söderkvist Peter, Linderholm Mats

Abstract excerpt

BACKGROUND: The single nucleotide polymorphism SNP309 with a change from T to G in the promoter region of the MDM2 gene is shown to increase the MDM2 protein levels and attenuate the p53 levels and associates with disease progression in several tumors. OBJECTIVE: In this study, the role of the polymorphism was investigated with regard to the clinical outcome in B-cell chronic lymphocytic leukemia (B-CLL)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Immunoglobulin Heavy Chains

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Prognosis

Share to Promoter Regions, Genetic

Share to Proto-Oncogene Proteins c-mdm2

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 20491880
DOI: 10.1111/j.1600-0609.2010.01470.x

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.PMID 20491880Read ↗

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.Semantic proximity Read ↗

Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.Semantic proximity Read ↗

MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.Semantic proximity Read ↗

The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.Semantic proximity Read ↗

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.Semantic proximity Read ↗

MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.Semantic proximity Read ↗

Association of MDM2 polymorphism with risk and prognosis of leukemia: a meta-analysis.Semantic proximity Read ↗

Correlations between MDM2 gene SNP309 polymorphism and susceptibility to leukemia.Semantic proximity Read ↗

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.Semantic proximity Read ↗

MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.Semantic proximity Read ↗

Association of breast cancer outcome with status of p53 and MDM2 SNP309.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.